New PD-L1 Inhibitor Could Make Mesothelioma Immunotherapy Safer
A new PD-L1 inhibitor may be on the horizon for people with malignant mesothelioma. A Phase I trial suggests it…
New drugs for mesothelioma, improvements in diagnostic tools and clinical trials give cancer patients more than a fighting chance. Read now.